Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioNxt Solutions Inc C.BNXT

Alternate Symbol(s):  BNXTF

Healthcare
BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active... see more

Recent & Breaking News (CSE:BNXT)

XPhyto Closes First Tranche of Financing

Accesswire March 31, 2022

XPhyto Provides Progress Update on Psychedelic Medicine Programs and Novel Compounds Milestone

Accesswire February 22, 2022

XPhyto Reports on its Three Primary Business Divisions

Accesswire February 8, 2022

XPhyto Executes Covid-ID Lab Sales Contracts with Test Clinics and Pharmacies in Germany as Part of Multi-Product Rollout Strategy

Accesswire February 1, 2022

XPhyto Provides Update on Integration of 3a-diagnostics GmbH

Accesswire January 24, 2022

XPhyto Announces Head of Sales, Europe

Accesswire January 17, 2022

XPhyto signs Distribution Agreement for Czech Republic, rollout planned for Hungary, Slovakia, Ukraine and Russia

Accesswire January 13, 2022

XPhyto Announces New Director of Business Development and Head of Diagnostic Research

Accesswire January 10, 2022

XPhyto Epilepsy Clinical Trial Planned in 2022 with Its Proprietary Fast-Dissolving CBD Oral Strips

Accesswire December 15, 2021

XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH

Accesswire December 6, 2021

XPhyto Therapeutics Announces Stock Option Grants

Accesswire December 3, 2021

XPhyto Therapeutics Closes Private Placements for Gross Proceeds of $7,000,0000

Accesswire November 26, 2021

XPhyto Announces CFO Appointment

Accesswire November 19, 2021

XPhyto Announces Managing Director Appointment, Financing and 3a-diagnostics Development

Accesswire November 3, 2021

XPhyto Reports Development Update for its Drug Delivery Business

Accesswire October 12, 2021

Xphyto Announces Engagement of Consultants for Marketing and Promotional Activities

Accesswire October 8, 2021

XPhyto Reports Successful Market Launch and Growing Demand for its 25-minute COVID-19 PCR Test COVID-ID Lab

Accesswire September 8, 2021

XPhyto Launches First Commercial Biosensor for Oral Disease

Accesswire August 30, 2021

XPhyto's Acquisition Target, 3a-Diagnostics, Reports Breakthrough Identification of COVID-19 Biosensor Candidates

Accesswire July 28, 2021

XPhyto Signs Transformative Acquisition Agreement With 3a-Diagnostics, to Enter Hi-Tech Biosensor Market and Expand Its Diagnostic Product Portfolio

Accesswire July 20, 2021